WOCKPHARMA.NSE Wockhardt Ltd.

Wockhardt has two molecules — Nafithromycin (WCK 4873) for treating pneumonia and WCK 5222 for urinary tract infection, in development phases, with launched lined up for FY25 and FY26

Other prominent names like ICICI Prudential, Mirae Asset Management, Tata Indian Opportunities Fund, Invesco India Smallcap Fund, Gagandeep Credit Capital and Subhkam Ventures were also issued shares in Wockhardt's QIP.

Sources familiar with the matter told CNBC-TV18 that the total issue size is anticipated to be Rs 570 crore, comprising an issue size of Rs 350 crore and a greenshoe option worth Rs 220 crore.

Wockhardt could be more of a research company in five years than what it is today.